Russia PREVENT (HIV Prevention Partnership in Russian Alcohol Treatment)

Status Completed

Clinical Trial Summary

The purpose of this study is to test an HIV prevention intervention in a Russian substance abuse treatment facility using a randomized trial study design.

Clinical Trial Description

A randomized controlled trial of an HIV prevention intervention in a narcology hospital using a stratified randomization design (by gender and substance use diagnosis) will be implemented.

We will conduct a trial among 180 inpatient subjects undergoing treatment at the LRCA. This adapted HIV prevention intervention (adapted Enhanced-RESPECT), Project RESPECT, is a 2-session, one-on-one HIV prevention counseling and testing activity with a trained health educator. By random assignment, half of the subjects will receive the Enhanced-RESPECT intervention, which will include 3 additional booster sessions. And half will receive CDC post-test counseling or standard of care depending on the results of their HIV antibody test. The post-test counseling will follow CDC counseling and testing guidelines. Subjects in the Control group who are not HIV-infected will receive the current standard of care in Russia for non-infected patients; receipt of negative test results by a clinician. HIV pre-test counseling occurs within the first 48 hours of patient arrival at LRCA. CDC post-test counseling guidelines represent a higher standard of care than currently exists within this facility for HIV-infected patients and is equivalent to the standard of care recommended for US HIV testing facilities.

All study participants will be evaluated regarding substance abuse and HIV risk behaviors at baseline and follow-up. Follow up interviews will take place at 3 time points (just before discharge from the hospital and at 3 and 6 months post-randomization). All Intervention participants will receive the basic 2-session adapted RESPECT intervention while inpatients; booster sessions for adapted Enhanced-RESPECT HIV Intervention participants will take place after discharge. Booster sessions will be offered once a month for 3 months. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00183118
Study type	Interventional
Source	Boston Medical Center
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	October 2004
Completion date	December 2005

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03340051` - Remote Alcohol Monitoring and Episodic Thinking	N/A
Completed	`NCT02901041` - Interdisciplinary Study of A Novel Anticonvulsant in Alcoholism	Phase 3
Not yet recruiting	`NCT06444243` - Psilocybin-assisted Therapy for Alcohol Use Disorder	Phase 2
Completed	`NCT02705898` - Lifestyle Physical Activity Intervention for Depressed Alcohol Dependent Women	N/A
Completed	`NCT02486900` - Neurofeedback & Alcohol Dependence	N/A
Completed	`NCT02179749` - Mifepristone Treatment of Alcohol Use Disorder	Phase 2
Completed	`NCT02197598` - Treatment of Patients Suffering of Alcohol Dependence and Impaired Liver Function With Selincro® As-needed Use	Phase 4
Recruiting	`NCT02385643` - The Efficacy of A Smartphone-based Support System to Reinforce Alcohol Abstinence in Treatment-seeking Patients	N/A
Completed	`NCT01828866` - Eye Movement Desensitization and Reprocessing (EMDR) in Alcohol Dependent Patients	N/A
Terminated	`NCT01408641` - Topiramate for Alcohol Use in Posttraumatic Stress Disorder	N/A
Active, not recruiting	`NCT01182766` - New Treatment for Alcohol and Nicotine Dependence	Phase 2/Phase 3
Completed	`NCT01342549` - Treatment Strategy for Alcohol Use Disorders in Veterans With TBI	Phase 3
Completed	`NCT02193204` - Chronic Alcohol, Stress Inflammatory Response and Relapse Risk	N/A
Completed	`NCT01176591` - HBPL Study of the Impact of the NK1 Antagonist Aprepitant	Phase 2
Completed	`NCT01165541` - A Study of Quetiapine and Mirtazapine for the Treatment of Alcohol Dependency	Phase 2
Completed	`NCT01056484` - Mindfulness Meditation for Health	Phase 2
Completed	`NCT00585780` - Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse	Phase 1/Phase 2
Completed	`NCT00607620` - Disseminating Organizational SBI Services at Trauma Centers	N/A
Completed	`NCT00884884` - Aripiprazole and Topiramate on Free-Choice Alcohol Use	Phase 2/Phase 3
Completed	`NCT00463346` - Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.